8-K: SELLAS Reports Strong Q2, Advances AML Pipeline

SELLAS Life Sciences announced positive Q2 2025 financial results and significant clinical progress for its AML therapies, GPS and SLS009.

Summary

• Reported a net loss of $6.6 million for Q2 2025, an improvement from $7.5 million in Q2 2024.
• Research and development expenses decreased to $3.9 million in Q2 2025 from $5.2 million in Q2 2024.
• General and administrative expenses increased to $3.0 million in Q2 2025 from $2.4 million in Q2 2024.
• Cash and cash equivalents totaled $25.3 million as of June 30, 2025, with an additional $4.0 million from warrant exercises in July 2025.
• The Independent Data Monitoring Committee (IDMC) issued a positive recommendation to continue the Phase 3 REGAL trial of GPS in AML without modification.
• Positive Phase 2 results for SLS009 in relapsed/refractory (r/r) Acute Myeloid Leukemia (AML) met all primary endpoints.
• SLS009 achieved a 44% response rate in AML-Myelodysplasia-Related Changes (AML-MRC) patients at an optimal dose of 30 mg twice weekly.
• Median overall survival (mOS) for SLS009 in AML-MRC patients was 8.9 months, significantly surpassing a historical benchmark of 2.4 months.
• FDA recommended advancing SLS009 into a first-line AML trial, with enrollment anticipated by Q1 2026.
• Preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer was presented at ASCO 2025.
• Expanded Scientific Advisory Board with three new oncology experts.
• Included in the Russell 3000 and Russell 2000 Indexes.
• Preclinical efficacy of SLS009 in T-Cell Prolymphocytic Leukemia (T-PLL) to be presented at ESMO 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical trial results for SLS009, exceeding historical benchmarks and gaining FDA support for a first-line trial. The GPS Phase 3 trial also received a positive IDMC recommendation. Financials show improved net loss and a healthy cash position, further bolstered by warrant exercises. These factors indicate significant progress and positive momentum for the company's pipeline.

Positives

• Net loss decreased to $6.6 million in Q2 2025 from $7.5 million in Q2 2024, and to $12.4 million in H1 2025 from $17.0 million in H1 2024.
• Basic and diluted loss per share improved to $0.07 in Q2 2025 from $0.13 in Q2 2024, and to $0.13 in H1 2025 from $0.33 in H1 2024.
• Positive IDMC recommendation to continue the pivotal Phase 3 REGAL trial of GPS in AML without modification, indicating a favorable risk-benefit profile and consistent efficacy data.
• SLS009 Phase 2 trial in r/r AML met all primary endpoints, demonstrating a 44% response rate in AML-MRC patients and 50% in AML-MRC with M4/M5 subtype, significantly exceeding the targeted 20% ORR.
• SLS009 achieved a median overall survival of 8.9 months in AML-MRC patients and 8.8 months in patients relapsed or refractory to venetoclax-based regimens, far surpassing the historical benchmark of 2.4 months.
• FDA alignment to advance SLS009 into a first-line AML trial, potentially supporting a New Drug Application (NDA) including accelerated approval.
• Strong cash position of $25.3 million as of June 30, 2025, bolstered by an additional $4.0 million from warrant exercises in July 2025.
• Inclusion in the Russell 3000 and Russell 2000 Indexes enhances visibility and liquidity.
• Strengthened scientific leadership with the addition of three world-class oncology experts to the Scientific Advisory Board.

Negatives

• General and administrative expenses increased by $0.6 million in Q2 2025 compared to Q2 2024, primarily due to professional fees, personnel-related expenses, and public company costs.

Risks

• Risks and uncertainties inherent in oncology product development and clinical success.
• Uncertainty of regulatory approval for new therapies.
• Other risks and uncertainties affecting development programs as detailed in the Annual Report on Form 10-K filed on March 20, 2025, and other SEC filings.

Future Outlook

The company anticipates the final analysis of the pivotal Phase 3 REGAL trial of GPS in AML by year-end 2025. Enrollment for the 80-patient first-line AML trial for SLS009 is expected to begin by Q1 2026, with the potential to support a New Drug Application (NDA), including accelerated approval. Preclinical efficacy data for SLS009 in T-PLL will be presented at ESMO 2025 in October.

Management Comments

• "We continue to make significant progress in advancing our AML-focused pipeline, as demonstrated by the positive Phase 2 results evaluating our novel CDK9 inhibitor, SLS009, for the treatment of r/r AML."
• "The Phase 2 trial met all primary endpoints, achieving a 44% response rate among patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML-MRC), which at the optimal dose level, nearly tripled the median overall survival compared to a historical benchmark."
• "Based on the strength of these data, we conducted an end-of-Phase 2 meeting and the FDA recommended advancing SLS009 into the front-line setting for AML. We are now preparing an 80-patient trial that is focused on newly diagnosed and early refractory to venetoclax and azacitidine AML patients, with enrollment anticipated to begin by Q1 2026."
• "With the final pivotal Phase 3 REGAL data of GPS in AML expected by year-end, positive Phase 2 data of SLS009 in r/r AML, and our upcoming ESMO presentation showcasing SLS009s impact in T-PLL, we enter the second half of 2025 with tremendous momentum and a clear focus on advancing our late-stage clinical programs and growing shareholder value."

Industry Context

The biopharmaceutical industry, particularly in oncology, is highly competitive and driven by clinical trial success and regulatory approvals. SELLAS's focus on Acute Myeloid Leukemia (AML) and other cancer indications places it in a high-need area. The positive Phase 2 results for SLS009, especially exceeding historical benchmarks and gaining FDA alignment for a first-line trial, position it favorably against competitors developing AML treatments. The continued progress of the GPS Phase 3 trial also indicates a robust pipeline in a challenging disease area. The inclusion in Russell indexes suggests growing market recognition within the small-cap biotech sector.

Comparison to Industry Standards

• SLS009's median overall survival (mOS) of 8.9 months in AML-MRC patients and 8.8 months in relapsed/refractory to venetoclax-based regimens patients significantly surpassed the historical benchmark of 2.4 months, indicating a substantial improvement over existing or historical treatment outcomes for this difficult-to-treat patient population.
• The 44% response rate for SLS009 in AML-MRC patients and 50% in AML-MRC with myelomonocytic/myelomonoblastic (M4/M5) subtype significantly exceeded the targeted 20% overall response rate (ORR), demonstrating strong efficacy compared to the trial's predefined success criteria.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, potential for accelerated approval, and improved financial health, which could lead to increased shareholder value.
• Patients: Potential for new, more effective treatment options for Acute Myeloid Leukemia (AML) and other cancer indications, especially given SLS009's strong efficacy data compared to historical benchmarks.
• Employees: Continued stability and growth opportunities as clinical programs advance and the company expands its pipeline.
• Regulatory Authorities: Engagement with the FDA for SLS009's path to market, indicating adherence to regulatory processes and potential for new drug approvals.

Next Steps

• Final analysis of the pivotal Phase 3 REGAL trial of GPS in AML anticipated by year-end 2025.
• Full data presentation for SLS009 Phase 2 results expected later this year.
• Preparation for an 80-patient first-line AML trial for SLS009, with enrollment anticipated to begin by Q1 2026.
• Presentation of preclinical efficacy of SLS009 in T-Cell Prolymphocytic Leukemia (T-PLL) at ESMO congress in Berlin, October 17-21, 2025.

Key Dates

Recommendation

The filing indicates substantial positive developments for SELLAS. The strong Phase 2 results for SLS009, particularly the significant improvement in median overall survival compared to historical benchmarks and the FDA's recommendation for a first-line trial, represent a major de-risking event and open a clear path to potential accelerated approval. The positive IDMC recommendation for the Phase 3 GPS trial further reinforces pipeline strength. While the company remains in a clinical stage with inherent risks, the clinical data presented, coupled with an improved net loss and a strengthened cash position, suggest a favorable outlook for future growth and potential market value appreciation. These factors make it an attractive investment for those seeking exposure to the oncology biotech sector.

Keywords

AML, Acute Myeloid Leukemia, Oncology, Biopharmaceutical, Clinical Trials, Phase 3, Phase 2, GPS, Galinpepimut-S, SLS009, CDK9 inhibitor, FDA, Drug Development, Cancer Therapy, ASXL1 mutation, T-PLL, Financial Results